Cancer Immunotherapy 102

Sunday, October 18, 2026

4:00 PM - 5:00 PM PT

Location: Petree Hall C

Moderator(s)

LS

Larissa Sweeny, MD

Associate Professor, Otolaryngology - Head and Neck Surgery
University of Miami Health System
Miami, Florida, United States

Panelist(s)

Joseph M. Curry, MD

Professor
Thomas Jefferson University
Wynnewood, PA, United States
RM

Rajarsi Mandal, MD

Associate Professor
Northwell Hofstra
New Hyde Park, NY, United States
Glenn J. Hanna, MD

Associate Professor; Center for Head and Neck Oncology
Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA, United States

Disclosure(s):

Joseph M. Curry, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Glenn J. Hanna, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

The second part of the Cancer Immunotherapy course will focus on recent advances in the field, including emerging biomarkers in oncology, ongoing clinical trials, applications in the neoadjuvant setting, and future directions in patient care. An understanding of both current developments and anticipated advances in immunotherapy is essential for effective patient counseling and informed clinical decision-making. This panel, geared toward general otolaryngologists, head and neck surgeons, and trainees, will provide an in-depth review of biomarkers, active clinical trials, and potential future immunotherapeutic agents. Emphasis will be placed on recent clinical trial results and landmark studies, ensuring the audience receives the most current and relevant evidence available.

Learning Objectives:

: Upon completion of this activity, the participants should have an understanding of new and emerging biomarkers in head and neck oncology.
Upon completion of this activity, the participants should have an understanding of ongoing clinical trials evaluating immunotherapies for treatment of head and neck cancer, including in the neoadjuvant setting.
Upon completion of this activity, the participants should have an understanding of new and emerging immunotherapies for head and neck cancer and future directions.